ADMA Biologics (ADMA) Competitors $17.72 +0.32 (+1.84%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ADMA vs. BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, PCVX, and QGENShould you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. ADMA Biologics vs. BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen ADMA Biologics (NASDAQ:ADMA) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Is ADMA or BGNE more profitable? ADMA Biologics has a net margin of 17.80% compared to BeiGene's net margin of -25.94%. ADMA Biologics' return on equity of 53.20% beat BeiGene's return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics17.80% 53.20% 26.07% BeiGene -25.94%-25.12%-14.95% Does the media prefer ADMA or BGNE? In the previous week, ADMA Biologics had 1 more articles in the media than BeiGene. MarketBeat recorded 9 mentions for ADMA Biologics and 8 mentions for BeiGene. BeiGene's average media sentiment score of 1.01 beat ADMA Biologics' score of 0.99 indicating that BeiGene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeiGene 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, ADMA or BGNE? ADMA Biologics has higher earnings, but lower revenue than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$382.81M10.78-$28.24M$0.2862.32BeiGene$3.32B5.21-$881.71M-$8.24-21.52 Do insiders & institutionals have more ownership in ADMA or BGNE? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 48.5% of BeiGene shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 7.4% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, ADMA or BGNE? ADMA Biologics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Do analysts rate ADMA or BGNE? ADMA Biologics presently has a consensus target price of $21.25, indicating a potential upside of 21.78%. BeiGene has a consensus target price of $253.69, indicating a potential upside of 43.04%. Given BeiGene's higher possible upside, analysts plainly believe BeiGene is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25BeiGene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community prefer ADMA or BGNE? BeiGene received 134 more outperform votes than ADMA Biologics when rated by MarketBeat users. However, 72.08% of users gave ADMA Biologics an outperform vote while only 69.24% of users gave BeiGene an outperform vote. CompanyUnderperformOutperformADMA BiologicsOutperform Votes41372.08% Underperform Votes16027.92% BeiGeneOutperform Votes54769.24% Underperform Votes24330.76% SummaryADMA Biologics beats BeiGene on 13 of the 19 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get ADMA Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADMA vs. The Competition Export to ExcelMetricADMA BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.13B$2.93B$5.16B$9.09BDividend YieldN/A1.91%5.12%4.26%P/E Ratio62.3245.8387.3217.12Price / Sales10.78407.891,157.79119.34Price / Cash386.28174.7643.2337.85Price / Book29.083.884.784.77Net Income-$28.24M-$42.00M$120.55M$225.50M7 Day Performance-8.06%-2.50%-1.55%-1.34%1 Month Performance-17.61%1.71%13.71%0.44%1 Year Performance311.56%16.80%28.65%15.39% ADMA Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADMAADMA Biologics3.7763 of 5 stars$17.72+1.8%$21.25+19.9%+310.4%$4.19B$382.81M63.29530BGNEBeiGene2.7991 of 5 stars$176.95-1.3%$253.69+43.4%+0.2%$17.24B$2.46B-21.7710,600MRNAModerna4.2655 of 5 stars$41.74-0.2%$79.50+90.5%-58.5%$16.06B$5.06B-7.195,600VTRSViatris1.8751 of 5 stars$12.70+0.6%$13.67+7.6%+17.6%$15.16B$15.05B-17.0738,000SMMTSummit Therapeutics3.1322 of 5 stars$18.27+2.5%$33.33+82.4%+654.0%$13.47B$700,000.00-63.68105GMABGenmab A/S4.237 of 5 stars$20.14-0.1%$45.20+124.4%-35.4%$13.33B$19.84B19.582,204High Trading VolumeRDYDr. Reddy's Laboratories1.1362 of 5 stars$14.77+2.1%$17.00+15.1%+14.1%$12.33B$299.87B22.9527,048SRPTSarepta Therapeutics4.7799 of 5 stars$127.00+2.7%$178.71+40.7%+25.8%$12.13B$1.64B98.971,314Positive NewsCTLTCatalent2.5919 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.5582 of 5 stars$90.74+3.4%$147.50+62.6%+41.7%$11.31BN/A-19.07160Analyst ForecastQGENQiagen3.6242 of 5 stars$45.44+0.1%$51.15+12.6%+0.3%$10.37B$1.97B117.035,967 Related Companies and Tools Related Companies BGNE Alternatives MRNA Alternatives VTRS Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives SRPT Alternatives CTLT Alternatives PCVX Alternatives QGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADMA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
